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1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer world-wide with approxi‐
mately 700,000 new cases a year, with increasing numbers in Europe and the United States [1].
The various risk factors are reflected in the worldwide heterogeneous incidence. The majority
of cases of HCC develop in eastern Asia and sub-Saharan Africa due to chronic infection with
hepatitis B virus (HBV), as well as aflatoxin. In other parts of the world such as Northern
America, Europe and Japan, the prevailing risk factor is chronic infection with hepatitis C virus
(HCV) and alcohol use [2]. Additional or synergistic factors include non-alcoholic steatohe‐
patitis (NASH), diabetes, obesity and tobacco, with their high prevalence in Northern America
offering a partial explanation for the continuously increasing incidence of HCC [3-6].
HCC develops in cirrhotic livers in 80% of cases, as cirrhosis is one of the strongest risk factors
given its role as a preneoplastic condition [7]. The mechanism itself is not fully known,
although it may be secondary to the disorderly architectural changes seen in the hepatic
parenchyma of the cirrhotic liver providing a signal for malignant transformation. Addition‐
ally, there could be a role for DNA damage caused by viral integration, as incidence of HCC
increases with viral load and duration of infection, thus raising the possibility of a cumulative
effect of long-term viral damage [8-9].
There has been major progress in understanding the nature of the disease, as well as the
available therapies. Although the full range of treatment options has increased over time,
especially with the advent of new surgical and molecular technologies, the mainstay of
treatment remains surgery, as the only truly therapeutic option. This chapter will discuss the
evaluation of the patient with HCC, the two main surgical treatments, liver resection and
orthotopic liver transplantation (OLT), as well as future prospects which include the molecular
classification of HCC and the efforts for targeted molecular therapies, which in turn will have
a great impact on any therapeutic decision.
© 2013 Tsoulfas and Agorastou; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Evaluation of patients with hepatocellular carcinoma
In order for surgical treatment for HCC to be successful, patients need to be chosen very
carefully. It is essential that the evaluation, selection and treatment are performed by multi‐
disciplinary teams that include hepatologists, surgeons, oncologists, radiologists, pathologists
and anesthesiologists. The reason is that we have to remember that we are dealing with more
than one problem in the same setting. Specifically, the patient’s HCC needs to be addressed,
but it has to be done in the setting of the possible cirrhosis. The degree that the patient’s liver
function is affected can have a direct impact on several other organ systems (cardiopulmonary,
renal) and thus directly influence any therapeutic decisions. It is interesting that, in contrast
to several other cancers, there are not many randomized controlled trials to compare the
treatments seen as curative for HCC, something which underscores the need for these patients
to be followed in protocols whenever possible, so that evidence-based decisions can be made.
The first question that has to answered is whether the patient is an operative candidate,
meaning whether the patient is in a position to undergo a major surgery from the standpoint
of his overall health. It is essential that this evaluation is performed by physicians who are
intimately aware of the challenges of liver resection or transplantation. For example, the
anesthesiologist has to be aware that this will be an operation with potential significant blood
loss and periods of hypotension, all of which will stress the cardiovascular system. This should
help determine the kind of preoperative testing that is needed, although there is to-date no
universally agreed upon preoperative protocol for patients undergoing liver resection. The
importance of this can be seen even more clearly if we consider that given the improvements
in surveillance and surgical technique and the general ageing of the population, older patients
belonging to a higher risk group are being increasingly evaluated for liver surgery. Once the
question of the patient as an operative candidate has been answered satisfactorily, the next
one is whether the HCC is resectable. The answer to this question depends on identifying the
stage of the disease, as well as the hepatic reserve of the patient.
2.1. Staging of patients with hepatocellular carcinoma
Regarding the stage, there is a lack of a common language as there is no consensus on a
universal staging system. There are different ones, each one taking slightly different aspects
of the disease into consideration. Some depend on clinical and radiological findings prior to
the treatment, whereas others are based on the histopathological findings. Ideally, clinically-
applicable staging for HCC should assess the tumor stage, the underlying liver function and
the patient’s biological status. Some of the staging systems, such as The American Joint
Committee on Cancer/Union Internationale Contre le Cancer Tumor-Node-Metastasis staging
system (AJCC/UICC TNM) stratifying patients into prognostic groups, are best suited to only
patients undergoing resection or transplantation, without taking into consideration the
underlying liver disease [10]. In an effort to consider tumor features and hepatic function, the
Okuda system and the Cancer of the Liver Italian Program (CLIP) classifications were
proposed [11-12]. Both of them have the ability to identify end stage disease but are not as
accurate with early stage disease. A step towards solving this problem has been the Japan
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Integrated Staging score, which combines the Child-Turcotte-Pugh (CTP) classification with
the simplified TNM system by the Liver Cancer Study Group of Japan (LCSGJ) [13].
The most widely accepted system appears to be the Barcelona Clinic Liver Cancer (BCLC)
system, which was introduced in 1999 as an attempt to improve on the Okuda system, so as
to include the functional aspect of the disease. It was developed based on a combination of
data from a variety of studies looking into different types of treatment for different stages of
the disease [14-16]. The BCLC takes into account the total cancer load, the stage of the cirrhosis
and the patient’s functional status, in an effort to determine the type of treatment necessary
and the expected survival (Figure 1). It is the staging system most widely (but not universally)
accepted, as it has been externally validated and it offers a pathway between staging and the
different treatment modalities with an estimation of life expectancy [17]. It provides suggested
treatments for the different stages of the disease, including early stage HCC where the aim is
a cure, as opposed to advanced HCC where palliative treatments are proposed. In addition to
providing proper patient care, universally-accepted staging for HCC is critical in allowing the
comparison between results from different studies in order to draw the appropriate conclu‐
sions. A system such as the BCLC, which is a clinical system with predictive abilities, can offer
a solid platform for the initial staging. Other systems, such as the simplified TNM, which
includes pathological findings such as microvascular invasion, can be of more value in those
patients undergoing resection or OLT.
Figure 1.
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2.2. Evaluation of hepatic reserve of patients with hepatocellular carcinoma
As far as evaluating the hepatic reserve of the patient is concerned, that is a determination of
both quantity and quality. This is a major change from the past when there were multiple
exclusion criteria, as the only ones that have been consistently validated over time are the
postoperative remnant liver volume and hepatic function [18-20]. It has been shown that if 3
or more hepatic segments are left behind after a resection, or an adequate hepatic remnant,
which is 25% for a normal liver and 40% for a cirrhotic one, then postoperative liver dysfunction
can be avoided [21-22]. This means that it is essential to be able to accurately estimate the liver
remnant and the future remaining liver volume preoperatively, especially in the case of
extended resections. The most reliable way to do this has been CT volumetry, which with the
advent of the Digital Imaging and Communications in Medicine (DICOM) standard has
enabled volumetry to be performed even by the surgeon on a personal computer. Quality can
be assessed either directly (liver biopsy) or indirectly, through assessment of the synthetic
function of the liver (INR, platelets, albumin) or other marks of portal hypertension and
cirrhosis, such as esophagogastroduodenoscopy (EGD) looking for varices. The underlying
chronic liver disease, including its duration and whether the patient has received any treat‐
ment, are also important pieces of information.
By fully evaluating the patient with HCC, one can proceed more safely into determining
whether the patient is a candidate for surgical treatment and which one: resection versus
transplantation. Frequently, it may be necessary for the patient to be evaluated for both, as a
patient undergoing a liver resection could show signs of hepatic failure postoperatively,
leading to a discussion of whether transplantation is an option. It is wise for these decisions
to be made beforehand, rather than during emotionally-charged times.
3. Hepatectomy
The first question one has to consider when discussing the issue of hepatic resection for HCC
is the presence or not of cirrhosis. In non-cirrhotic patients, hepatic resection represents the
preferred treatment, as the lack of cirrhosis means that the patient can tolerate even an
extended resection, and the non-cirrhotic liver will allow future re-resection, although it has
a lower chance of de novo recurrence. Unfortunately, these patients without cirrhosis represent
only 5% of cases in the West [23]. Even so, in these patients without cirrhosis, surgical resection
for HCC can lead to 3-year survival of 46-76% and 5-year survivals of 30-50%, depending on
the selection criteria and on whether fibrolamellar HCC cases are included in the study [24-26].
A high recurrence rate at 5 years of around 60% remains, even after potentially curative
resections, possibly owing to intrahepatic metastases rather than existing disease, as the effect
of the underlying chronic liver disease and the cirrhosis is not present [27].
In  patients  with  cirrhosis,  using  proper  selection  criteria  to  avoid  postoperative  hepatic
failure  is  critical.  That  set  of  criteria  was  originally  based on  the  Child-Pugh classifica‐
tion, which however was not shown to have a consistent predictive value, as patients may
show signs of hepatic dysfunction even at a stage of Child-Pugh A, thus making a resection
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a high-risk one [28]. The best candidates for liver resection, and those who could achieve
5-year survivals of up to 70%, are those patients with single lesion, asymptomatic HCC,
and most  importantly with preserved liver  function [29-31].  The definition of  preserved
liver function includes the absence of clinically significant portal hypertension (hepatic vein
wedge pressure  difference  less  than 10mmHg,  absence  of  varices  or  splenomegaly,  and
platelets over 100,000/mm3) and normal bilirubin values [32].  In patients with significant
portal  hypertension,  5-year survival  after resection goes down to 50%, whereas in those
with combined portal hypertension and increased bilirubin levels it can be as low as 25%
[33]. In order to predict the risk of postoperative hepatic insufficiency other groups have
used the Model for End-stage Liver Disease (MELD) score, which is based on the values
of the patient’s creatinine, bilirubin and prothrombin time. Several studies have shown that
when the MELD score is 9 or less,  then hepatic resection can be safe with almost mini‐
mal chances of postoperative patient destabilization [33-35].
The preference for patients with a single lesion has to do with the fact that in most cases
multifocal HCC is associated with decreased survival and increased recurrence, potentially as
an indication of already existing intrahepatic metastases. Although not prohibitive for
resection, the presence of multiple lesions should alert the surgeon to the possibility of using
treatments such as radiofrequency ablation and chemoembolization in combination with
resection to obtain optimal results. Similar to multifocality, an increased tumor size is not
necessarily prohibitive, but can serve as an indication of possible vascular invasion, which can
in turn negatively affect the prognosis. When all of this is considered, the percentage of patients
that can undergo hepatic resection under ideal conditions is less than 10%. However, even in
this group of patients with cirrhosis, it is possible to achieve moderate long-term results [36-38].
3.1. Considerations in liver resection
When considering liver resection for HCC apart from the main question of the presence or
absence of cirrhosis, there are other key issues to be addressed, such as ways to increase
resectability, the differences between anatomic and non-anatomic resection and the use of
laparoscopic surgery among others.
3.1.1. The role of portal vein embolization
In  an  effort  to  treat  large  HCC with  hepatic  resection  or  in  those  patients  with  inade‐
quate  liver  remnant,  there  are  certain  preoperative  manoeuvres  that  can  help  increase
resectability in these challenging patients. Preoperative portal vein embolization (PVE) was
introduced in 1986 by Kinoshita  to  prevent  postoperative hepatic  insufficiency,  whereas
Makuuchi had first introduced the concept to clinical practice in 1982 for the treatment of
hepatic cholangiocarcinoma [39-40]. The main principle is to occlude the portal venous flow
to the side of the tumor, and cause ipsilateral atrophy and, more importantly, contralater‐
al hypertrophy of the part of the liver that will be the future remnant after the resection.
This can lead to an increase in the future remnant by about 20-40% within 4-6 weeks, thus
potentially increasing the pool of candidates for resection [41-43].  Although there are no
absolute contraindications, especially as experience with the procedure continues to grow,
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there are some relative ones, including uncorrectable coagulopathy, tumor invasion of the
portal vein, biliary dilatation and renal failure. Bilobar disease used to be a contraindica‐
tion, however in light of the increased use of the two-stage hepatectomy, PVE can play a
significant  role  in  these  patients  [42,44].  Although there  are  two methods  to  access  the
portal  vein for PVE, the transileocolic and the percutaneous transhepatic one,  with both
being equally effective,  the percutaneous procedure has the distinct advantage of avoid‐
ing a minilaparotomy and general anesthesia. Regarding the choice of embolic agents, there
is a great variety with similar results. However, since it is not an exact science how much
embolic material or what size particles are needed to cause a specific amount of hypertro‐
phy and regeneration, we need to understand that this procedure is very much operator-
dependent. Certain principles need to be closely adhered to, such as embolizing till stasis
is achieved, and also avoiding reflux of the embolic material into the veins that will supply
the future liver remnant.
There are some remaining concerns regarding PVE, such as whether PVE may stimulate the
growth of hepatic tumor (of more interest in the case of hepatic metastases from colorectal or
other cancers), or whether it is a safe procedure in patients with high-grade varices. The
difficulty in answering these questions is the fact that we lack an understanding of the
mechanism involved in the contralateral hypertrophy caused by the PVE. It is probably a
combination of hepatic and extrahepatic factors, including cytokines (such as IL-6), growth
factors (such as hepatocyte growth factor) and nutrient factors (insulin and glucagon),
although the details are not yet clear [45]. Either way, PVE provides the surgical team with an
important tool that if properly applied can lead to increased resectability of HCC.
3.1.2. Anatomic versus non-anatomic hepatic resection
Hepatic resection for malignant tumors can be anatomic or nonanatomic. The anatomic
approach involves a resection of liver segments based on the segmental anatomy, whereas the
nonanatomical approach involves a resection of the tumor with negative margins. The main
argument in favour of the anatomic resection was made by Makuuchi and the Japanese school
of thought, where based on the fact that HCC tends to metastasize via the portal venous system,
it is believed that removing the tumor along the lines of hepatic segments, which would include
the portal flow to the tumor, is the more oncologically sound approach [46-47]. Using a nation-
wide Japanese database of 72,744 patients to compare the outcome of anatomic versus
nonanatomic resection for HCC, it was shown that there was no difference in overall survival,
although with anatomic resection there was an improved disease-free survival [48]. The
beneficial effect of anatomic resection was most prominent for HCC lesions 2 to 5 cm, some‐
thing which was explained by the fact that in smaller tumors there is very little chance of
vascular invasion, whereas in bigger ones the high probability of vascular invasion and satellite
lesions negates any advantage of an anatomic resection. Despite this, the extent of the hepa‐
tectomy should be primarily dictated by the extent of the existing chronic liver disease and the
future liver remnant.
This type of argument has given impetus to the use of nonanatomic resection for HCC, as in
the vast majority of cases the HCC occurs in the background of cirrhosis. Even so, the question
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remains of what the proper margin for the nonanatomic resection is. Specifically, there is an
ongoing debate as to whether a margin of 1cm or more is necessary to obtain disease-free
survival, or whether less than 1cm is sufficient [49-51]. A prospective, randomized trial
comparing narrow (1cm) to wide (2cm) resection margins identified a significant 5-year
survival benefit (75% versus 49%) for the wide margin group, especially in patients with small
HCC of 2cm or less [52]. Even so, a report by the Japan Society of Hepatology in 2010 states
that “it is acceptable to resect a tumor with a minimum width so as to avoid exposing the tumor
during hepatectomy for HCC” [53].
3.1.3. Laparoscopic liver resection
Although the first laparoscopic liver resection (LLR) was performed in 1992 by Gagner, it
has  been  somewhat  of  an  uphill  struggle  because  of  several  reasons  [54].  Potential
difficulties of LLR include a significant learning curve, the perceived difficulty in control‐
ling  hepatic  bleeding  should  it  occur,  the  lack  of  tactile  sense  which  could  affect  the
margins obtained and thus the oncological  result  of  the procedure,  the fear  of  port  site
metastases and that of gas embolism. To all of these we should add the lack of random‐
ized  trials  with  LLR.  Improvements  in  hepatic  surgery,  as  well  as  in  laparoscopic  sur‐
gery,  advances  in  the  laparoscopic  instruments  used,  and  patient  interest  in  minimally
invasive procedures, have all led to a significant increase in the number and type of LLRs.
There has also been increased use of LLRs for hepatic malignancies, as currently more than
half  of  all  LLRs are  for  primary or  metastatic  hepatic  malignancies,  including anatomic
lobectomies  and  liver  resections  in  cirrhotic  patients  [55-58].  The  key  factor  is  surgeon
experience and the learning curve, as in one paper it was shown that the learning curve
for minor laparoscopic hepatectomy could be overcome with 60 cases [59].  The surgeon
needs to be a liver surgeon with knowledge of hepatic anatomy, as well as someone with
experience in advanced laparoscopic surgery, so that issues such as control of vascular or
biliary  structures  can  be  dealt  with  laparoscopically.  Additionally,  experience  with
laparoscopic  ultrasound  is  mandatory,  as  it  counterbalances  the  lack  of  tactile  sense.
Common sense dictates that at least the earliest laparoscopic procedures performed by a
surgical  team  should  include  smaller,  peripheral  lesions  away  from  major  vascular
structures or the hilum that can be approached with a laparoscopic wedge or segmental
procedure.
In the case of HCC, several series have shown a good long-term outcome without jeopardizing
patient safety [60-62]. Some of the findings in these studies included decreased blood loss and
transfusion requirements for LLR, as well as a shorter length of stay. Although the latter may
come as no surprise given the minimally invasive nature of the procedure, the former could
be potentially attributed to new and improved coagulation and transection devices used in
LLR. Another advantage of LLR is the possible decreased risk of hepatic function destabiliza‐
tion, if we consider that most of these patients have cirrhosis. It is believed that the lack of the
big abdominal incisions, can cause less of an effect on the portal pressure, thus decreasing the
risk of postoperative hepatic decompensation [63-64]. The result of the decreased biological
and surgical stress for the patient could also be part of the reason why it was shown that prior
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LLR for HCC facilitated salvage liver transplantation with improved results compared to prior
open liver resection [65].
3.1.4. HCC recurrence after resection
HCC recurrence after hepatic resection is a significant concern with reported rates between
60-70% at 5 years [66-68]. The challenge lies in deciding what the best treatment for these
patients is. The options include a second resection versus radiofrequency ablation versus
salvage liver transplantation. Evaluating radiofrequency ablation has not been easy as there
are significant variations in the inclusion criteria used in the various studies. Regarding OLT,
an analysis of the UNOS database by Pelletier et al. reported a 61% 5-year intention to treat
survival of patients with tumors within Milan criteria [69]. However, there have been studies
advocating the use of a second resection in properly selected patients. In the largest study in
the Western world a 5-year 67% overall survival was reported from a second resection after
HCC recurrence, with the two main risk factors being gross vascular invasion and time to
recurrence from primary resection less than a year [70]. It should be noted though that when
these strict criteria were used, only 15% of patients with recurrence were candidates for a
second resection.
3.1.5. Liver resection as a bridge to OLT
The issue of HCC recurrence raises an important question. When discussing the different
surgical treatments of HCC, it is imperative to stress the fact that liver resection and OLT are
not necessarily competitive surgical options, but can very frequently be seen as complimen‐
tary. Specifically, the cirrhotic patient who undergoes a hepatectomy for a HCC, no matter
how stable the liver function is, certainly runs the risk of peri- or post-operative liver failure,
thus necessitating an urgent evaluation and referral for OLT. The implication here is that
patients with HCC and cirrhosis should be evaluated for both liver resection and OLT and
preferably be treated at a center where both options are available.
4. Orthotopic liver transplantation for HCC
Patients suffering from cirrhosis and HCC that are not candidates for resection, either because
of the degree of liver disease or the location or anatomy of the tumor, are best treated by OLT.
The main advantage is that OLT provides a solution for both the cirrhosis and the HCC. The
problem arises from the fact that there is a limited organ supply, and for that reason there have
been criteria established for patients to enter the waiting list. The most frequently used ones
are the Milan criteria (single lesion less or equal to 5 cm in size or three or no more than three
lesions, none of which are over 3cm in size), which can lead to 5-year survival of 70% [9]. There
has been an effort to expand these criteria, as it has been shown that moderate expansion in
terms of number and/or size of the lesions can lead to comparable survival.
This chapter will analyze the following issues having to do with OLT and HCC: a) results for
OLT for HCC and criteria used to prioritize these patients, b) the practice of bridging therapies
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to OLT and downstaging prior to OLT, and c) the role of living donor liver transplantation
(LDLT) for OLT.
4.1. Results and criteria for OLT for HCC
As mentioned above the most consistent prognostic  factors regarding OLT for HCC are
derived from the characteristics originating from the Milan criteria having to do with the
size  and  number  of  the  lesions,  in  addition  to  no  macrovascular  involvement  and  no
extrahepatic metastatic disease to lymph nodes, lungs, bones, or other abdominal organs.
These criteria can lead to 5-year survival of around 70% and recurrence-free survival of
70-80% [70-71]. In properly selected patients, it is possible to achieve even long-term results
that  are  more  than  satisfactory  with  9-year  survival  of  52%  [72].  Getting  to  this  point
however has been challenging, as there is a continuous need to reevaluate the listing and
priority criteria for OLT for HCC.
Originally,  HCC  was  considered  a  contraindication  for  OLT  given  the  dismal  patient
survival  rates that  were the result  of  patients  being transplanted at  a  very late  stage of
their  cancer,  as  the technique was still  considered experimental.  The combined work of
Bismuth in 1993 and the subsequent Milan criteria by Mazzaferro showed that if patients
were carefully chosen, so that the lesions were within a certain number and size, then it
was  possible  to  achieve  these  excellent  results  with  OLT  for  HCC  [70,  73].  Recently,
however,  several  groups have argued that the Milan criteria are too restrictive and that
more patients with HCC could benefit from OLT. The strongest argument along these lines
is based on the University of California San Francisco (UCSF) criteria (single HCC lesion
up to 6.5cm diameter or up to three lesions,  none larger than 4.5cm, with a cumulative
diameter  of  8cm)  [74].  Another  retrospective  study with  the  largest  number  of  patients
outside the Milan criteria  has shown encouraging outcomes by using the “up-to-seven”
rule [75].  This approach uses the sum of the combination of size and number covariates
equal  to seven or less.  Although it  appears as a strong proposal  to expand the existing
criteria, it does have the disadvantage of being based on post-transplant pathology. All of
this has led many to discuss the “metroticket” theory, which is based on the belief  that
the further you go (the more you expand the existing criteria), the higher is the price you
will  be  forced to  pay  (decreased survival  and increased recurrence)  [76].  In  the  United
States, where the MELD score is used for listing, patients within the Milan criteria receive
22  MELD  exception  points  for  transplantation  priority  [77].  Despite  an  additional  10%
increase  in  MELD  every  3  months,  patients  may  end  up  waiting  6  months  to  a  year,
depending on the region that they are [77].
4.2. Bridging therapy to OLT for HCC
The fact that, despite receiving extra priority points on the waiting list, patients with HCC may
still have to wait significantly and risk falling outside the Milan criteria, makes the issue of
bridging therapy all the more important. Bridging therapy is mainly aimed towards patients
that are already within Milan criteria and thus eligible for OLT, and for whom the goal is to
avoid tumor progression while on the waiting list. Although it is hard to clarify the usefulness
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of bridging therapy for patients with HCC, mainly because of the retrospective nature of most
studies on the topic, it has been shown that the drop-out rate while on the waiting list increases
as waiting time progresses, especially in the case of HCC [78]. Based on the estimates that have
formed the basis of the UNOS MELD score exception policy, it is suggested to use bridging
therapies for T2 patients, even if the estimated waiting time is less than 3 months [79].
Regarding the question of which therapy is best for bridging, the most promising therapy
appears to be radiofrequency ablation, as several studies have shown decreased drop-out in
radiofrequency ablation pretreated patients with a single HCC nodule [80-81]. Additionally,
there may be a role for transarterial chemoembolization (TACE) for patients with lesions larger
than 3cm or with a multinodular pattern, although this has not been verified in prospective
studies. Another possibility, which is currently under investigation, is the use of transarterial
radioembolization with Uttrium-90 microspheres, with promising results to this point [82-83].
4.3. Downstaging therapy for HCC prior to OLT
Downstaging refers to the effort made in patients that find themselves outside the Milan or
UCSF criteria for transplantability, to decrease their tumor burden to the extent that they fall
within these criteria again. This way, these patients become candidates for OLT. Additionally,
it is thought that the response to downstaging and the maintenance of this response represent
a surrogate marker of the aggressiveness of the tumor, which in itself could help guide any
decisions regarding the transplantability of a patient [84]. As to which the best method for
downstaging is, TACE appears to have the advantage for single treatment, especially for
multifocal tumors [84]. Even so, the combination of TACE, radiofrequency ablation and
resection seems to be an even more effective method of downstaging compared to TACE alone
(70% success versus 40%) [83, 85].
4.4. The role of living donor liver transplantation in the management of HCC
For many, LDLT represents a possible solution to the organ shortage problem and the long
waiting list; for others it presents an opportunity for an aggressive approach in dealing with
HCC patients whose tumors are outside the accepted criteria (such as the Milan and UCSF
ones), if a suitable living donor exists. Currently in the US, LDLT represents about 5% of all
liver transplantations. Despite the fact that the experience with LDLT is still being accumu‐
lated, there appears to be significant optimism. In one of the bigger studies from Japan with
316 patients undergoing LDLT for HCC, one- and three-year survivals were 78% and 69%
respectively, whereas recurrence-free one- and three-year survivals were 73% and 65% [86].
Although these results may not seem as impressive at first, it should be noted that 54% of these
patients were outside the Milan criteria, thus representing a higher risk group. Some studies
have shown improved survival for patients undergoing LDLT compared to those undergoing
OLT from deceased donors, with 1-year survival of 86% for LDLT versus 71% for deceased
donor recipients [87]. Despite these encouraging results, there remains a lot of concern. The
main reason is the consideration that the health of the living donor is placed at risk, as living
donors are in the unique situation of undergoing a major surgical procedure without any
health benefit to themselves. Additionally, regarding the argument of expanding HCC criteria
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for patients undergoing LDLT, since they have their own living donor, the question remains
of what should happen if these recipients suffer hepatic dysfunction or nonfunction of the liver
graft. That is, should they be listed in the deceased donor waiting list, something which would
not have been possible before, given the size or number of their lesions. The answer at this
point appears in most cases to be “no” and thus these are all considerations that should be
carefully addressed by the surgical and medical teams before proceeding with a LDLT for
HCC. Finally, as it has been seen in one of the bigger, multicenter trials in the US, the Adult-
to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL), although the survival
results between recipients of deceased donor and living donor transplantation are similar,
there appears to be a higher chance of recurrence after the LDLT of 29% versus 0%, despite the
much shorter waiting time (160 days for LDLT versus 469 days for deceased donor OLT) [88].
However, this could also be because of the shorter waiting time, as some would argue that by
being able to proceed to transplantation quickly, one loses the “opportunity” to evaluate the
biological behavior of the HCC.
5. Future challenges
Given the significant developments and progress in surgical technique, the biggest challenge
in the treatment of HCC is identifying the biological behavior of a given tumor, so that a
patient-tailored, or rather a tumor-targeted, treatment can be applied. To do this, it is necessary
to identify those factors, other than tumor size and number, that determine tumor aggressive‐
ness. Several studies have identified a variety of parameters, such as the response to chemo‐
embolization, the presence of microvascular invasion, the degree of differentiation and the
combination of total tumor volume (TTV) together with AFP as surrogate markers for the
tumor’s biological behavior [89-93]. Regarding the latter, in an overview of the Scientific
Registry of Transplant Recipients data from March 2002 to January 2008, it was shown that
AFP>400 ng/ml or TTV>115 cm3 led to a three-year survival of less than 50% [94]. Essentially,
this represents a novel approach, where the issue is not necessary the number or size of the
HCC lesions per se, but rather the total tumor load.
The most promising area in terms of defining the nature and behavior of HCC is that of
molecular biology, with the use of genetic markers. Currently, identification of targets such as
vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor
(PDGFR) has led to medications being used in clinical practice for advanced HCC, such as
sorafenib and imatinib [95-98]. More importantly, the identification of microRNAs (miRNAs),
which are a non-protein coding family of genes regulating gene expression, has opened a new
window to the future. Specifically, they have been shown to function as oncogenes and tumor
suppressor genes, making this a very useful screening tool for potential resection or liver
transplantation candidates [99-100]. Several miRNA targets have been identified, with
prominent among them miR-122a and miR-21, with the former being down-regulated and the
latter up-regulated in HCC [101-102]. Advances in understanding the multistep process that
is hepatic carcinogenesis, as well as beginning to identify the different signaling cascades
involved, has provided researchers and clinicians with the opportunity to proceed with
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molecular classification of HCC [103-104]. This will provide critical information in terms of
assessing the biological behavior of different HCCs, which in turn can help improve the
therapeutic decision-making process.
6. Conclusion
Hepatocellular carcinoma is a disease with a far-reaching effect globally. The main therapeutic
treatment method remains surgery, with the two options being liver resection or orthotopic
liver transplantation. This chapter has discussed patient evaluation and selection for the
different therapies, the advantages and disadvantages of liver resection and transplantation
(with special emphasis on the fact that they both have a role in the continuum of care for these
patients), and the future challenges and opportunities provided by the molecular tools
available to today’s surgeon.
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